Bayer’s Finerenone Expands Its Reach in Chronic Kidney Disease

Bayer’s Finerenone Expands Its Reach in Chronic Kidney Disease

By, Admin 18 March 2026

A big win. A broader patient pool. And a potential shift in how non-diabetic CKD is treated.

Bayer has announced that its Phase 3 FIND-CKD trial has successfully met its primary endpoint—bringing new momentum to finerenone (marketed as Kerendia) in non-diabetic chronic kidney disease (CKD).

What Just Happened?

The FIND-CKD trial evaluated finerenone in patients with CKD without diabetes, a large and often overlooked group.

Key Result

  • Finerenone showed a statistically significant improvement in kidney function decline
  • Measured using eGFR slope (a key indicator of kidney health)
  • Compared to placebo, on top of standard care

Why this matters:

  • eGFR slope is a validated predictor of kidney failure risk
  • Slowing decline = delaying or preventing dialysis and transplant

Even better:

  • The drug was well tolerated, consistent with its known safety profile

Why This Is a Big Deal?

Let’s talk scale.

  • 850 million people globally live with CKD
  • More than half have non-diabetic CKD
  • Yet this group is underrepresented in treatment guidelines

The Reality of Non-Diabetic CKD

Common causes include:

  • Hypertension
  • Glomerulonephritis (like IgA nephropathy)

Risks are severe:

  • High chance of kidney failure
  • 2.6x higher risk of fatal cardiovascular events
  • Dialysis survival rate: ~40% at 5 years

In short: massive unmet need.

What Makes Finerenone Different?

Finerenone is not just another CKD drug.

Mechanism

  • A non-steroidal mineralocorticoid receptor antagonist (nsMRA)
  • Blocks MR overactivation, which drives:
    • Kidney damage
    • Inflammation
    • Fibrosis
    • Cardiovascular complications

Proven Track Record

Finerenone has already shown benefits in:

  • CKD with type 2 diabetes
  • Heart failure with reduced ejection fraction

Now, FIND-CKD extends that evidence into non-diabetic populations.

Inside the FIND-CKD Trial

This wasn’t a small study.

Trial Snapshot

  • 1,500+ patients
  • Broad range of CKD causes
  • Randomized into:
    • Finerenone (10 mg or 20 mg)
    • Placebo

All patients received standard care, including:

  • ACE inhibitors
  • ARBs

What They Measured

Primary endpoint:

  • Annual rate of eGFR decline over 32 months

Secondary endpoints:

  • Kidney failure
  • ≥57% drop in eGFR
  • Heart failure hospitalization
  • Cardiovascular death

Safety endpoints:

  • Adverse events
  • Serious adverse events
  • Hyperkalemia

Bayer’s Bigger Strategy: Dominating Cardio-Renal Space

This result isn’t standalone. It’s part of a much larger play.

The THUNDERBALL Program (CKD)

Includes:

  • FIDELIO-DKD
  • FIGARO-DKD
  • FIND-CKD
  • FINE-ONE

The FINEOVATE Platform

  • 10 Phase 3 studies across CKD and heart failure
  • Includes programs like:
    • MOONRAKER (heart failure)
    • THUNDERBALL (kidney disease)

Translation: Bayer is building a full-spectrum cardio-renal franchise.

What Happens Next?

  • Full data to be presented at a scientific conference
  • Regulatory submissions planned to expand Kerendia’s label
  • Target: approval in non-diabetic CKD patients

If approved:

  • Kerendia could become one of the first widely used therapies in this underserved segment

The Bottom Line

This is more than a trial success.

It’s:

  • A validation of finerenone’s mechanism across disease types
  • A step toward closing a major treatment gap
  • A signal that the cardio-renal space is heating up fast

For millions of patients with non-diabetic CKD, this could mean one thing: Slower disease. Better outcomes. More time.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!